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Abstract
Inhibition of N-myristoyltransferase has been validated pre-clinically as a target for the treatment of fungal and
trypanosome infections, using species-specific inhibitors. In order to identify inhibitors of protozoan NMTs, we chose to
screen a diverse subset of the Pfizer corporate collection against Plasmodium falciparum and Leishmania donovani NMTs.
Primary screening hits against either enzyme were tested for selectivity over both human NMT isoforms (Hs1 and Hs2) and
for broad-spectrum anti-protozoan activity against the NMT from Trypanosoma brucei. Analysis of the screening results has
shown that structure-activity relationships (SAR) for Leishmania NMT are divergent from all other NMTs tested, a finding not
predicted by sequence similarity calculations, resulting in the identification of four novel series of Leishmania-selective NMT
inhibitors. We found a strong overlap between the SARs for Plasmodium NMT and both human NMTs, suggesting that
achieving an appropriate selectivity profile will be more challenging. However, we did discover two novel series with
selectivity for Plasmodium NMT over the other NMT orthologues in this study, and an additional two structurally distinct
series with selectivity over Leishmania NMT. We believe that release of results from this study into the public domain will
accelerate the discovery of NMT inhibitors to treat malaria and leishmaniasis. Our screening initiative is another example of
how a tripartite partnership involving pharmaceutical industries, academic institutions and governmental/non-
governmental organisations such as Medical Research Council and Wellcome Trust can stimulate research for neglected
diseases.
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Introduction
Protozoan parasites are major causative agents of global
infectious diseases that affect millions of people in tropical and
sub-tropical regions of the world [1]. In the absence of effective
vaccination strategies, treatment for many of these infections
depends on chemotherapy and is reliant on ‘‘old’’ drugs that have
often been in use for long periods; were originally developed for
other types of disease; give rise to increasing levels of microbial
resistance; and often show unacceptable levels of toxicity. There is
a pressing need for new therapeutics that can be targeted to the
populations that need them. This work focuses on two groups of
diseases: the leishmaniases (caused by species of the kinetoplastid
parasite, Leishmania) and malaria (caused by species of the
apicomplexan parasite, Plasmodium).
In the case of the leishmaniases (a spectrum of diseases
associated with immune dysfunction), there are estimated to be
1.5–2 million new cases each year in 88 countries around the
globe, with 350 million people at risk and a disease burden of,2.4
million disability-adjusted life years [2,3]. Clinical symptoms,
ranging from the disfiguring skin lesions of cutaneous leishmaniasis
to the often fatal visceral leishmaniasis (VL – predominantly
caused by Leishmania donovani) are exacerbated in children and
immuno-compromised patients, such as those diagnosed as HIV
positive. Pentavalent antimonials have been the first-line treatment
for VL since the 1930s but these compounds are toxic, with
resistance an increasing problem in the Indian sub-continent [4].
While significant progress has been made in the last 10 years, with
the approval of lipid formulations of amphotericin B, miltefosine
and paromomycin, none of these has been developed by rational
design, and resistance may still be a problem. There is no effective
vaccine available, although vaccination should theoretically be
possible against these infections that can ‘‘self-heal’’ in their most
benign states. Thus new strategies for vaccination and chemo-
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therapy, particularly for visceral leishmaniasis (VL), remain an
urgent international priority [5].
Malaria remains one of the most important infectious diseases of
the developing world. There were an estimated 216 million episodes
in 2010, resulting in between 650,000 and 1.2 million deaths,
according to two recent reports, with over 90% occurring in Africa
[6,7]. Although P. falciparum accounts for 75% of malaria cases and
most of the deaths, P. vivax is also a significant problem in South East
Asia, and South and Central America [8]. There is an urgent need
to develop new drugs with rapid efficacy, minimal toxicity and low
cost to replace chloroquine and pyrimethamine-sulphadoxine
(available as Fansidar), which are failing rapidly due to resistance
in P. falciparum [9–11]. The use of artemisinin and its derivatives,
such as artesunate or artemether, which have good efficacy but very
short half-lives, together with longer acting agents such as
amodiaquine or lumefantrine in artemisinin-based combination
therapy (ACT), offers some respite. However these drugs are
expensive, development of resistance is an ever present possibility,
and new effective drugs will be required [12]. In addition it is
important to develop new drugs that also target blood stage sexual
forms of the parasite to prevent transmission, particularly of drug
resistant parasites [13]. At a recent Malaria Forum, the Gates
Foundation [14] called for the eradication of malaria. This goal will
realistically only be achieved by supplementing current control
methods with the development of vaccines and new drugs.
The disease statistics above make a compelling case for
accelerated drug development, which should be facilitated by
recent rapid progress in genome sequencing and subsequent post-
genomic strategies for target identification [12,15]. Numerous
targets have been assessed, including pyrimidine biosynthesis [16],
nucleotide signalling [17], kinase pathways [18] and lipidation
[19]. Inhibition of prenylation has shown potential to treat malaria
and more recently, lipid modification through inhibition of N-
myristoylation has shown encouraging progress.
Co–translational myristoylation is catalysed by the monomeric
enzyme myristoyl CoA: protein N-myristoyltransferase (NMT) in
all eukaryotes and has been shown to be essential for viability in
fungi and protozoa, through both genetic studies and by chemical
inhibition of Candida albicans NMT [20,21] and Trypanosoma brucei
NMT (Tb NMT) [22,23]. Our earlier work on the NMTs of T.
brucei (the kinetoplastid causative agent of African sleeping sickness)
[24–26], L. major [26] (causative agent of cutaneous leishmaniasis)
and P. falciparum (Pfal) [27,28], identified NMT as a suitable
candidate for drug development against the diseases caused by
these protozoan organisms [29,30].
NMT from Tb has already been demonstrated to be a druggable
target using small molecules (Figure 1) [22,23]. In addition, NMTs
from fungal species e.g. C. albicans and Aspergillus fumigatus have also
been long-standing targets within the pharmaceutical industry and
several inhibitor series have been reported [20,21,31]. With the
exception of the Searle series, which are peptidomimetics based on
the C. albicans Arf protein, all other published NMT inhibitor series
were obtained by high-throughput screening.
Structures of representative inhibitors bound to their respective
NMT targets are available and each shows inhibitors binding in the
same region as the substrate peptide. A wide variety of proteins are
reported or predicted as substrates for myristoylation based on an
N-terminal consensus sequence for substrates (GXXXSK/L) [32].
The broad scope of amino acids that are tolerated close to the amino
terminal is a reflection of a relatively wide channel, which can be
used to rationalise the diversity of the inhibitor structures. The
published molecular structures from the fungal and T. brucei NMT
programs were used to overlay the ligands in a common co-ordinate
frame, (Figure 2), and could be used to rationalise the observed
selectivity e.g. for fungal vs. protozoan NMTs.
The presence of compounds from the legacy Searle and Pfizer
fungal NMT programs, within the Pfizer corporate collection, has
made screening of the Pfizer file an attractive option for the
identification of inhibitors of Plasmodium and Leishmania NMTs
[33–35]. In this study, we extend the scope of screening to sample
the diversity of the entire Pfizer compound file.
Due to time and cost constraints, we decided to limit our primary
screening campaign to ,150,000 compounds from the Pfizer
Global Diverse Representative Set [36], against both PfalNMT and
L. donovani (Ldon) NMT since these protozoan NMTs are sufficiently
dissimilar at the sequence level to warrant separate screens. Activity
of hit compounds would be confirmed in replicated dose-response
assays to generate a preliminary SAR for each target.
All mammalian systems studied to date have been shown to
have two NMT genes, nmt1 and nmt2 [37]. HsNMT1 has been
shown to be essential for embryonic development in mice, whilst
the physiological role of HsNMT2 is currently unknown [38].
However, a number of oncogenic proteins are substrates of human
NMTs, and certain viruses and bacteria also exploit host NMTs to
myristoylate their own proteins. Consequently, human NMTs
have been proposed as targets for the treatment of cancer and viral
infections [29]. To date, there have been no conclusive reports on
the potential toxicity of mammalian NMT inhibition in vivo, but in
view of the essential role of NMT in mammalian development,
selectivity over human NMTs is desirable. All hits from this study
should therefore be screened in dose–response assays against both
human isoforms HsNMT1 & HsNMT2 (Hs1 & Hs2). Hits might
also be tested against the NMT from Tb, since activity against
multiple protozoan NMTs would be an advantage, provided
selectivity over human NMTs could be achieved.
Methods
P. falciparum and L. donovani NMT screening
Recombinant P. falciparum [39] (Swiss-Prot Q81LW6) and L.
donovani NMTs [40] (EMBL accession number FN555136) were
produced at the University of York, using established protocols. An
assay format based on scintillation proximity technology to monitor
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enzyme activity was used as previously described [27,30]. This
radioactive format provides a quantification of the N-myristoylation
of the synthetic peptide CAP5.5 (derived from the N-terminus of the
T. brucei CAP5.5 protein) [41] as used in [22,24], and was modified
to a 384-well plate screening format with a final volume of 40 ml.
The Pfizer Global Diverse Representative Set [36] consisting of
150,000 compounds was screened at 20 mM final assay concen-
tration. Assay plates were prepared by dispensing 0.1 mL of
compound dissolved in DMSO using the Vario system (Cybio)
into white 384-well plates (Greiner Bio-One). The assay buffer
consisted of 30 mM Tris-HCl pH 7.4, 0.5 mM EGTA, 0.5 mM
EDTA, 0.1% Triton X-100 and 1.25 mM DTT.
Enzyme solution containing the appropriate NMT (Pfal at
3.7 nM final assay concentration, Ldon at 0.84 nM) diluted in
assay buffer was added to each well in a volume of 10 ml using a
Multidrop Combi dispenser (Thermo Scientific). Plates were
incubated for 15 min at room temperature (RT) before the
addition of substrate solution, consisting of cold myristoyl CoA
(Sigma), 3H-myristoyl CoA (ARC) and CAP5.5 at the respective
final assay concentrations of 54 nM, 8.5 nM and 250 nM.
The reaction was initiated by adding 10 mL of the substrate
mixture to each well containing the pre-incubated enzyme/
compound mixture, and allowed to proceed at RT for 80 min.
The reaction was quenched by the addition 20 ml of stop solution
to each well. Stop solution consisted of 0.75 M MgCl2 (Sigma),
0.1 M phosphoric acid (Sigma) and 1 mg/ml of streptavidin-
coated polystyrene SPA beads (Perkin-Elmer). Plates were sealed
using topseals (Perkin-Elmer) and left overnight to allow the bead
solution to settle. Radioactive counts were measured with an
integration time of 300 sec per plate using the Leadseeker
Figure 1. Structures of representative, previously reported NMT inhibitor series. Three distinct series of C.albicans NMT inhibitors,
exemplified by SC-58272, UK-370485 and compound 5 [31] , and a series of inhibitors of both T.brucei and L.donovani NMT (e.g. DDD85646), have
been reported in the chemical literature. Co-crystal structures with their respective targets have shown that each inhibitor binds in the same region of
the binding site as the substrate peptides (Figure 2).
doi:10.1371/journal.pntd.0001625.g001
Protozoan N-myristoyltransferase Inhibitors
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Generation 4 plate reader (GE Healthcare). Each plate included a
positive control of 1 mM final assay concentration of DDD85646
[22] and 1% DMSO as a negative control. Hit compounds were
further titrated using a through-plate IC50 format with a top
concentration of 80 mM, and 12 points with a 1:2 dilution step.
The data were analysed using Pfizer SIGHTS software and
visualised using Spotfire software (TIBCO).
T. brucei and Human NMT screening
Additional dose-response assays using the T brucei NMT [22,24]
(EMBL FN554973) and human enzymes HsNMT1 [39](Swiss-
Prot P30419) and HsNMT2 [39](Swiss-Prot O60551), produced at
the University of York using established protocols, were carried
out to assess the activity spectrum of hit compounds. The assay
format used was the same as above, however the respective
concentrations of the enzymes were 4.8 nM, 2.6 nM and 2.6 nM,
respectively. Substrate concentrations were 108 nM myristoyl
CoA, 17 nM 3H-myristoyl CoA and 500 nM CAP5.5 (final assay
concentration) for all three specificity screens. The stop solution
had a reduced SPA bead concentration of 0.5 mg/ml. The Tb
NMT screen reaction incubation was 60 min, while the Hs1 and
Hs2 reaction incubation was 15 min. The same dose-response
format of 80 mM top concentration and a 12-point curve, with a
1:2 dilution step was used.
Results
Analysis of Previous NMT Inhibitors
While the reported NMT inhibitors all occupy the substrate
peptide-binding site, structural studies on C. albicans NMT have
shown that distinct inhibitor series exploit different interactions
with the protein (Figure 2). Consequently, we envisaged that a set
of high-throughput screening hits would be likely to represent a
number of different binding modes. We anticipated that a different
binding mode might result in a different selectivity profile against
the set of NMTs in this study. In the case of the recently reported
TbNMT inhibitors, the lead compound is reported to have
equivalent potency against both HsNMT1 and L. major NMT [22].
In contrast, our previous work had shown that even a single
residue change in the binding region of C. albicans NMT was
sufficient to result in a three-hundred-fold loss of enzyme affinity
[35].
Figure 3. Comparison of protein identity and similarity for the
NMT isoforms in this study. Figure showing the percentage
sequence identity (Blue) and sequence similarity (Yellow) as defined
by BLAST between the NMT proteins from L. donovani (LdonNMT, EMBL
accession number FN555136), P. falciparum (PfalNMT, Swiss-Prot
Q81LW6), T. brucei (TbNMT, EMBL FN554973) and the catalytic domains
of Human NMT isoforms Hs1NMT1 (Swiss-Prot P30419) and Hs2NMT
(Swiss-Prot O60551.
doi:10.1371/journal.pntd.0001625.g003
Figure 2. Overlay of structures of inhibitors (see Figure 1) based on alignment of binding site residues. The crystal structural
information for NMTs from fungal (C. albicans, Saccharomyces cerevisiae), human and protozoan (L. major and L donovani) NMTs was used as the basis
for modelling work. The binding-site residues were aligned to create a view of the occupation of the NMT binding sites across species (based on 1iyl,
2wsa, 1iyk, and an unpublished structure for UK-370485 in C. albicans NMT). Images were created using the Pfizer molecule-modelling package MoViT
and the inhibitors colored (Yellow: SC-58272: Orange: Compound 5 [31]; Green: UK-370485; Pink: DDD85646). Despite binding in the same region of
their respective NMT, each compound occupies a different sub-region, which supported the case for high-throughput screening as a source of novel
NMT inhibitor series.
doi:10.1371/journal.pntd.0001625.g002
Protozoan N-myristoyltransferase Inhibitors
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We hypothesised that the number of global residue changes
between the NMT proteins would correlate with increasingly
divergent SAR for the various NMT proteins in this study.
Publically available sequence information was used to calculate
pairwise similarity and identity between the NMT proteins in the
study (Figure 3). Although an ideal compound would have broad-
spectrum activity against the protozoan NMTs but would lack
activity against both human NMTs, our analysis suggested that
this could difficult to achieve, unless some distinct differences in
the binding sites could be exploited. The sequence similarities
suggest that it should be more likely for Ldon NMT hits to be
selective over Pfal and HsNMTs, but that PfalNMT hits would be
less likely to achieve selectivity over HsNMTs.
P. falciparum and L. donovani NMT screening
The Pfal and Ldon HTS generated Z9 scores of 0.84 and 0.78,
respectively, indicating that the screening results were of excellent
quality [42]. In order to capture all potential actives, compounds
conferring above 40% inhibition were considered to be hits, giving
an overall hit rate of 0.8% and 0.4%, respectively, with 0.1% of
the compounds being classified as hits against both NMTs. Since
the Pfizer file consists of discrete clusters of compounds, either
from parallel synthesis libraries or medicinal chemistry series, we
used this series of origin definition, rather than a clustering
algorithm, to label the series. Encouragingly, hit series tended to
inhibit one of the target NMTs selectively. All hits were progressed
to dose-response assays using a top concentration of 80 mM. Hits
were classified as confirmed if they gave a measured IC50 of
,5 mM against either enzyme. They were further sub-divided into
selective inhibitors of either NMT or both enzymes (Figure 4). The
activities of the most potent example from selected, novel series of
NMT inhibitors is summarised in Table 1 (see Figure 5 for
structures of the hit molecules). Several other series identified in
the primary screen were discarded due to low potency, lack of
selectivity or due to on-going interest for other Pfizer programs.
As our initial high-throughput screen sampled only around 5%
of the Pfizer screening collection, we sought to expand our hit
identification through further analogue screening. Several ap-
proaches were employed including substructure searching, simi-
larity searching and by the creation of Bayesian activity models
based on the primary screening data [43]. However, the most
successful tool used local hit rates to identify hit rich series (Table 1)
[44]. In two series, we were able to identify more potent hits from
further screening (compounds in Table 1 without local hit rate
value). Further series with low local hit rate values tended to be
weakly active on repeat testing.
When selecting series for further follow-up, we focused on
compounds with selective activity against either NMT and with a
ligand efficiency (LE) of greater than 0.30 [45–47]. Unlike gene
families such as GPCR antagonists or kinase inhibitors, we had
insufficient data on transferase enzymes to guide our expectations
for the level of LE that might be attained in a drug candidate.
However, the level we achieved is consistent with those achieved
by peptidomimetic protease inhibitors. Consequently, we believe
that all of the series exemplified have sufficiently high ligand
efficiency to warrant further development as lead compounds.
T. brucei and Human NMT screening
2066 compounds were selected for wider profiling against a
panel of NMT orthologues, based on either activity in the primary
Figure 4. Bar chart showing numbers of active compounds in each chemical series. Compounds with .40% activity against either Ldon
[red], Pfal [yellow] or both NMT targets [blue], were sub-divided by chemical series. Most of the series were selective for one NMT orthologue.
Molecules active against both targets were often highly active against one NMT and weakly active against the other primary screening target.
doi:10.1371/journal.pntd.0001625.g004
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Figure 5. Structures of representative hit compounds from NMT screening. Triage of the primary screening hits made use of local hit rate
analysis; ligand efficiency against the primary target; selectivity in the primary screen; and broader NMT selectivity. Eight of the series were judged to
contain lead compounds capable of further development towards new medicines to treat malaria or leishmaniasis. Table 1 summarises the primary
screen activity of selected preferred examples from each series and a further series representative when analogue screening identified a superior
compound. The broader NMT screening profile of each compound is detailed in Table 2.
doi:10.1371/journal.pntd.0001625.g005
Table 1. Primary dose-response profile of representative hits from each chemical series.
Series Compound ID # hits Pfal LHR Pfal IC50 Pfal LE Ldon IC50 Pfal/Ldon Sel
Glycinyl 3-aminopyrrolidine CP-854190 30 0.03 1.72 0.34 38.7 22.5
Benzimidazolemethylamine PF-03665853 47 0.04 0.91 0.32 .80 .88
Aminomethylindazoles PF-02378143 15 0.11 2.54 0.38 65.4 25.8
Azetidinopyrimidines PF-03531549 9 0.04 1.7 0.27 1.2 0.7
Azetidinopyrimidines PF-03531814 9 n/a 0.482 0.31 72 150
Series Compound ID # hits Ldon LHR Ldon IC50 Ldon LE Pfal IC50 Ldon/Pfal Sel
Aminoacylpyrrolidines PF-03402619 12 0.07 0.901 0.29 .80 .88
Aminoacylpyrrolidines PF-03402623 12 n/a 0.093 0.35 71.9 770
Piperidinylindoles PF-03393842 13 0.21 0.102 0.37 9.0 88.5
Thienopyrimidines PF-00349412 5 0.14 0.482 0.34 39.6 82
Biphenyl derivatives PF-00075634 4 0.09 0.158 0.29 .80 .505
# Hits are compounds in series with activity ,5 mM against the respective NMT. LHR = Local hit rate @ 0.4 similarity to indicate the proportion of similar compounds
with activity in the primary screen. IC50 data are the mean of 3 separate experiments (in mM). These data were used to calculate ligand efficiency (LE) for each
compound against their target NMT, and to derive selectivity (Sel) values for the primary screening targets.
doi:10.1371/journal.pntd.0001625.t001
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screen or chemical similarity, to generate a pharmacological
profile of each NMT in the study, relative to each other. The
compound set included three biotin derivatives, which were known
to be false positives in this assay format and were shown to have
equivalent activity against each NMT orthologue, thus acting as
additional positive controls.
Two key findings emerged from this study. Firstly, we found
that the vast majority of the Pfal NMT hit series were equipotent
against both human NMTs (Figure 6 data shown for Hs1). Only
two series (azetidinopyrimidines and aminomethylindazoles)
showed a divergent SAR for Plasmodium vs. human NMTs (see
Table 2 for data on representative compounds), and in the case of
the azetidinopyrimidine series, selectivity was only observed in
some derivatives.
Secondly, and in contrast to the Pfal findings, there was no
correlation between activity against Ldon NMT and human NMTs
(Figure 7 for Hs1). In addition, the Leishmania NMT hits were
selective over both other protozoan NMTs (Table 2). Our study
also provided an insight into the selectivity profiles between
human NMTs and Tb NMT (Figures S1 and S2).
Discussion
We have exploited knowledge of the essential function of NMT in
protozoa, and harnessed the strength of the Pfizer compound
collection, to initiate a drug discovery program for this target in
Plasmodium and Leishmania. 150,000 compounds were screened
against Pfal and Ldon NMTs. Based on initial modelling studies and
sequence alignments, we opted to assess the quality of the hits
through selectivity assays against both Hs NMT isoforms and
against TbNMT, to assess their potential to deliver broad-spectrum
anti-protozoan NMT activity. Our results suggest that this objective
Table 2. Activity of lead compounds against all NMT orthologues in this study.
Series Compound ID Pfal IC50 Ldon IC50 Tb IC50 Hs1 IC50 Hs2 IC50
Glycinyl 3-aminopyrrolidine CP-854190 1.72 38.7 .80 0.57 1.59
Benzimidazolemethylamine PF-03665853 0.91 .80 35.4 0.51 0.56
Aminomethylindazoles PF-02378143 2.54 65.4 .80 38.9 56.3
Azetidinopyrimidines PF-03531549 1.7 1.2 52.7 11.5 16.1
Azetidinopyrimidines PF-03531814 0.48 72 .80 70.0 76.0
Aminoacylpyrrolidines PF-03402619 .80 0.90 9.9 47.2 63.6
Aminoacylpyrrolidines PF-03402623 71.9 0.093 1.5 5.2 14.7
Piperidinylindoles PF-03393842 9.0 0.10 35.9 73.2 64.1
Thienopyrimidines PF-00349412 39.6 0.48 56.2 9.0 11.5
Biphenyl derivatives PF-00075634 .80 0.16 .80 36.1 26.7
All data are in mM. Pfal and Ldon NMT values are the mean of 3 determinations, Hs1, Hs2 and Tb NMT IC50 values were from a single determination.
doi:10.1371/journal.pntd.0001625.t002
Figure 6. Plot of dose-response activity against Pfal vs. Hs1 NMTs for primary screening hit and analogue screening set. Broader
selectivity screening was carried out using 5 NMT orthologues and a set of 2066 compounds. A plot showing the potency of each compound against
Pfal and Hs1 showed that most compounds lacked selectivity. All compounds included in the broad selectivity screening were labelled with their
chemical series. The series with potential for further follow-up are disclosed in this paper. The other series were discarded due to lack of enzyme
activity or NMT-selectivity. Two series stood out from the general trend; representative structures for these series are shown in Figure 5. Two
additional series provided potent, non-selective inhibitors, which may also be useful as starting points for medicinal chemistry programs.
doi:10.1371/journal.pntd.0001625.g006
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is unlikely to be successful since we found that selectivity between
the protozoan NMTs is readily achievable but that most Pfal NMT
inhibitors are equipotent against the human isoforms. These results
suggest that Pfal/human NMT selectivity might be a barrier to drug
discovery for this target, unless inhibition of mammalian NMTs is
shown to have no toxicological effects. However, we discovered two
novel series with sufficient selectivity to encourage further medicinal
chemistry follow-up. These findings suggest that some compound
series are binding in regions that differ between Pfal and human
NMTs. If these differences can be rationalised, ideally through
obtaining co-crystal structures with Plasmodium NMT, even non-
selective hits could be of potential value as starting points for
medicinal chemistry programs.
Despite a lower initial screening hit rate, we found four series of
Ldon NMT inhibitors with good to excellent selectivity over all
other NMTs in our panel. While this result was in line with our
predictions for human and Pfal NMTs, the separation of Ldon and
Tb activity was unexpected. This result contrasts with those
previously reported for another series of Tb NMT inhibitors,
therefore suggesting that all of the series we have identified bind in
a different region of the binding pocket [23]. This observation will
be tested through further structural studies with Leishmania NMT.
It also appears that Ldon NMT is more susceptible to potent
inhibition, perhaps an indication that the peptide-binding site is
smaller than for the other NMTs in this study. Based on the results
we describe, it is also likely that high throughput screening of the
Pfizer file against other NMT orthologues would have yielded
further selective series. These results underline the benefit of high-
throughput screening of a diverse compound collection to discover
novel protozoan NMT inhibitors, as an alternative to a ‘‘piggy-
backing’’ approach [19].
This early drug discovery collaboration was facilitated by grants
from theWellcome Trust andMRC, which demonstrates the power
of such public private partnerships in bringing together the drug
discovery expertise of pharmaceutical companies and the detailed
target knowledge from academia to accelerate drug discovery for
neglected tropical diseases. Our most promising compounds are
disclosed to accelerate the pace of drug development for malaria
and leishmaniasis. These hits represent excellent starting points for a
future medicinal chemistry program, although they have yet to be
tested in whole cell assays against their target organisms. Our future
work on Pfal and LdonNMTs will focus on the translation of enzyme
inhibition into functional activity.
Supporting Information
Figure S1 Plot of dose-response activity against Ldon
vs. Tb NMTs for primary screening hit and analogue
screening set. While data reported for the series exemplified by
DDD85646 showed equal potency against both Ldon and Tb
NMTs, a plot of potency against Ldon and Tb NMTs showed that
activity did not correlate across the wider screening set The
combination of these data with those in previous Figures suggests
that broad-spectrum anti-protozoan NMT inhibition is unlikely to
be achievable.
(TIF)
Figure S2 Plot of dose-response activity against Hs1 vs.
Hs2 NMTs for primary screening hit and analogue
screening set. Data for the wider screening set against both
human NMTs showed an excellent correlation. Since the human
NMTs have the most similar sequences of all of the orthologues in
this study, there is no evidence from this analysis that selective
inhibition will be achievable.
(TIF)
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Figure 7. Plot of dose-response activity against Ldon vs. Hs1 NMTs for primary screening hit and analogue screening set. In contrast
to Figure 6, a plot of potency against Ldon and Hs1 NMTs showed that activity did not correlate. Excellent selectivity was observed for several
chemical series. The structures of representative members of four series are given in Figure 5.
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